Loading...

PE anti-human TNF-α Antibody

Pricing & Availability
Clone
MAb11 (See other available formats)
Regulatory Status
RUO
Other Names
Tumor necrosis factor-α, Cachectin, Necrosin, Macrophage cytotoxic factor (MCF), Differentiation inducing factor (DIF), TNFSF2
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
MAb1
PMA/Ionomycin-stimulated human PBMCs were stained with CD3 PE/Cy5 and MAb11 PE
  • MAb1
    PMA/Ionomycin-stimulated human PBMCs were stained with CD3 PE/Cy5 and MAb11 PE
See PE spectral data
Cat # Size Price Quantity Check Availability Save
502908 25 tests 82€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
502909 100 tests 196€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

TNF-α is secreted by macrophages, monocytes, neutrophils, T cells, and NK cells. Many transformed cell lines also secrete TNF-α. Monomeric human TNF-α is a 157 amino acid protein (non-glycosylated) with a reported molecular weight of 17 kD. TNF-α forms multimeric complexes; stable trimers are most common in solution. A 26 kD membrane form of TNF-α has also been described. TNF-α binding to surface receptors elicits a wide array of biological activities including: cytolysis and cytostasis of many tumor cell lines in vitro, hemorraghic necrosis of tumors in vivo, increased fibroblast proliferation, and enhanced chemotaxis and phagocytosis in neutrophils.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
E. coli-expressed, recombinant human TNF-α
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
FC - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA or ELISPOT Detection: The biotinylated MAb11 antibody is useful as the detection antibody in a sandwich ELISA or ELISPOT, when used in conjunction with the purified MAb1 antibody (Cat. No. 502802/502804) as the capture antibody.

Flow Cytometry3,5,6,10: The fluorochrome-labeled MAb11 antibody is useful for intracellular and membrane-bound immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.

Additional reported applications (for the relevant formats) include: neutralization1,2, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections4 and acetone-fixed frozen tissue sections8, immunocytochemistry7, and immunofluorescence9. The MAb11 antibody can neutralize the bioactivity of natural or recombinant TNF-a.

Note: For testing human TNF-a in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430201 to 430206) are specially developed and recommended. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of human TNF-a bioactivity (Cat. No. 502922).

The Purified MAb1 antibody is useful in neutralization2 and as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated MAb11 antibody (Cat. No. 502904/502914) as the detecting antibody.

Clone MAb11 cross-reacts to Cat11

Application References
  1. Rathjen D, et al. 1991. Mol. Immunol. 28:79. (Neut)
  2. Ablamunits V, et al. 2010. Eur. J. Immunol. 40:2891. (Neut)
  3. Enr quez J, et al. 2002. Adv. Perit. Dial. 18:177. (ICFC)
  4. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC)
  5. Chen H, et al. 2005. J. Immunol. 175:591. (ICFC)
  6. Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed
  7. Andersson U, et al. 2000. J. Exp. Med. 192:565. (ICC)
  8. Moormann AM, et al. 1999. J. Infect. Dis. 180:1987. (IHC)
  9. Zhao XJ, et al. 2003. J. Immunol. 170:2923. (IF)
  10. Rieger R, et al. 2009. Cancer Gene Ther. 1:53-64. (FC)
  11. Maksaereekul S, et al. 2009. Vaccine. 28:3754 (FC)
Product Citations
  1. Guimarães F, et al. 2017. J Pediatr (Rio J). 10.1016/j.jped.2017.08.005. PubMed
  2. Chen D, et al. 2018. Nat Commun. 9:873. PubMed
  3. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  4. Kuranda K, et al. 2018. J Clin Invest. 128:5267. PubMed
  5. Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed
  6. Almeida VG, et al. 2017. Braz J Med Biol Res. 50:e5163. PubMed
  7. Picard E, et al. 2019. Oncoimmunology. 8:e1527498. PubMed
  8. Ryzhov S, et al. 2019. J Am Heart Assoc. 8:e010874. PubMed
  9. Carestia A, et al. 2019. Cell Rep. 28:896. PubMed
  10. Jiang G, et al. 2020. Aging (Albany NY). 12:11466. PubMed
  11. Chang ZL, et al. 2020. Nature Protocols. 15(4):1507-1524.. PubMed
  12. Pham TNQ, et al. 2020. Cell Reports. 29(9):2770-2782.e5.. PubMed
  13. Kagoya Y, et al. 2018. Nat Med. 24:352. PubMed
  14. Rochman Y, et al. 2015. PLoS One. 10:122198. PubMed
  15. Liu Y, et al. 2015. J Immunol. 194:5851. PubMed
  16. Liu B, et al. 2015. J Virol. 89: 11834 - 11844. PubMed
  17. Chruewkamlow N, et al. 2016. PLoS One. 11: 0145983. PubMed
  18. Kessler B, et al. 2017. Sci Rep. 7:42791. PubMed
  19. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  20. Zhu X, et al. 2020. Int J Biol Sci. 2.227777778. PubMed
  21. Oh DY, et al. 2020. Cell. 181:1612. PubMed
  22. Roudko V, et al. 2020. Cell. 183(6):1634-1649.e17. PubMed
  23. Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed
  24. Ma X, et al. 2021. Cell Metabolism. 33(5):1001-1012.e5. PubMed
  25. Loo Yau H, et al. 2021. STAR Protocols. 2(2):100549. PubMed
  26. Witkowski M, et al. 2021. Nature. 600:295. PubMed
  27. Schmidt S, et al. 2021. Vaccines (Basel). 9:. PubMed
  28. Rice TF, et al. 2021. EBioMedicine. 72:103612. PubMed
  29. Pi J, et al. 2022. J Nanobiotechnology. 20:36. PubMed
  30. Zhou Z, et al. 2022. J Gastrointest Oncol. 13:732. PubMed
  31. Port JR, et al. 2020. J Virol. 94:. PubMed
  32. Zhang B, et al. 2022. J Exp Med. 219:. PubMed
  33. Hubbard JM, et al. 2022. Clin Cancer Res. 28:2818. PubMed
  34. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  35. Zinngrebe J, et al. 2022. EMBO Mol Med. 14:e14901. PubMed
  36. Dai Z, et al. 2022. Signal Transduct Target Ther. 7:85. PubMed
  37. Pan YG, et al. 2022. Methods Mol Biol. 2574:31. PubMed
  38. Kim JH, et al. 2020. Sci Rep. 10:1835. PubMed
  39. Cheng H, et al. 2023. Nat Metab. 5:314. PubMed
  40. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  41. Yang Y, et al. 2023. MBio. 14:e0328522. PubMed
  42. Ribeiro MS, et al. 2023. Methods Mol Biol. 2618:289. PubMed
  43. Battistello E, et al. 2023. Mol Cell. 83:1216. PubMed
  44. van Os BW, et al. 2023. Eur Heart J Open. 3:oead013. PubMed
RRID
AB_315260 (BioLegend Cat. No. 502908)
AB_315261 (BioLegend Cat. No. 502909)

Antigen Details

Structure
TNF superfamily; dimer/trimer; 17 kD (Mammalian)
Bioactivity
Paracrine/endocrine mediator of inflammatory and immune functions; selectively cytotoxic for transformed cells; chemoattractant
Cell Sources
Activated monocytes, neutrophils, macrophages, T cells, B cells, NK cells, LAK cells
Cell Targets
Monocytes, neutrophils, macrophages, T cells, fibroblasts, endothelial cells, osteoclasts, adipocytes, astroglia, microglia
Receptors
TNFRSF1A (TNF-R1, CD120a, TNFR-p60 Type β, p55); TNFRSF1B (TNF-R2, CD120b, TNFR-p80 Type A, p75)
Cell Type
Neutrophils, Tregs
Biology Area
Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. Beutler B, et al. 1988. Annu. Rev. Biochem. 57:505.
3. Beutler B, et al. 1989. Annu. Rev. Immunol. 7:625.
4. Tracey K, et al. 1993. Crit. Care Med. 21:S415.

Regulation
Type II integral membrane protein processed by TACE for secretion; upregulated by interferons, IL-2, GM-CSF, substance P, bradykinin, PAF, immune complexes, cyclooxygenase; downregulated by IL-6, TGF-β, vitamin D3, prostaglandin E2, PAF antagonists
Gene ID
7124 View all products for this Gene ID
UniProt
View information about TNF-alpha on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 3    Revision Date: 09.06.2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account